文献速递头颈与中枢神经肿瘤

高肿瘤突变负荷与头颈癌根治性放化疗不良预后相关

Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
PubMed 文献 · Eur J Cancer · 2019-06-04

该多中心回顾性研究在101例接受根治性放化疗的局部晚期头颈鳞癌患者中,用327基因panel评估肿瘤突变负荷(TMB)与预后的关系。高TMB与TP53突变增加及非T细胞炎症型免疫表达相关,且与总生存显著缩短独立相关(HR 1.79,95%CI 1.02-3.14,P=0.042),TCGA队列验证一致。

要点

  • 高TMB头颈鳞癌患者根治性放化疗后总生存显著缩短。
  • 高TMB与TP53突变富集及非T细胞炎症免疫表达模式相关。
  • 高TMB患者可能更适合放化疗联合免疫检查点抑制剂的策略。

核心结论

  • 高TMB识别出根治性放化疗后预后不良的头颈鳞癌患者,这类患者可能优先从放化疗联合免疫检查点抑制剂中获益。

研究设计与样本

  • 多中心回顾性研究,纳入101例统一接受根治性放化疗的局部晚期头颈鳞癌患者,对治疗前石蜡包埋肿瘤样本行327基因靶向二代测序。
  • 在40例亚组中用nanoString平台进行肿瘤RNA免疫相关基因表达谱分析,并在TCGA头颈鳞癌队列中验证TMB的预后价值。

主要发现

  • 327基因panel估算TMB准确性高。
  • 高TMB与TP53突变患病率增加及与T细胞炎症基因表达谱无关的免疫基因表达模式显著相关。
  • Kaplan-Meier分析显示高TMB组总生存显著降低(死亡风险比1.79,95%CI 1.02-3.14,P=0.042),多因素模型校正混杂因素后仍显著。
  • TMB的预后价值在TCGA头颈鳞癌队列中得到证实。

临床怎么用

  • 对局部晚期头颈鳞癌患者可考虑检测TMB,高TMB提示根治性放化疗后预后较差。
  • 高TMB患者可作为放化疗联合免疫检查点抑制剂临床研究的优先候选人群。

局限性

  • 回顾性研究设计,样本量有限。
  • 免疫表达谱分析仅限40例亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumour mutational burden (TMB) estimated from whole exome sequencing or comprehensive gene panels has previously been established as predictive factor of response to immune checkpoint inhibitors (ICIs). Its predictive value for the efficacy of concurrent chemoradiation (cCRTX), a potential combination partner of ICI, remains unknown. METHODS: The accuracy of TMB estimation by an in-house 327-gene panel was established in the Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma (HNSCC) data set. Interference of TMB with outcome after cCRTX was determined in a multicentre cohort of patients with locally advanced HNSCC uniformly treated with cCRTX. Targeted next-generation sequencing was successfully applied in 101 formalin-fixed, paraffin-embedded pretreatment tumour samples. In a subset of cases (n = 40), tumour RNA was used for immune-related gene expression profiling by the nanoString platform. TMB was correlated with TP53 genotype, human papilloma virus (HPV) status, immune expression signatures and survival parameters. Results were validated in the TCGA HNSCC cohort. RESULTS: A high accuracy of TMB estimation by the 327-gene panel was established. High TMB was significantly associated with an increased prevalence of TP53 mutations and immune gene expression patterns unrelated to T cell-inflamed gene expression profiles. Kaplan-Meier analysis revealed significantly reduced overall survival in the patient group with high TMB (hazard ratio for death: 1.79, 95% confidence interval: 1.02-3.14; P = 0.042) which remained significant after correcting for confounding factors in the multivariate model. The prognostic value of TMB was confirmed in the TCGA HNSCC cohort. CONCLUSION: High TMB identifies HNSCC patients with poor outcome after cCRTX who might preferentially benefit from CRTX-ICI combinations.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Eder T, Hess AK, Konschak R, et al. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. Eur J Cancer. 2019. PMID: 31173964. doi:10.1016/j.ejca.2019.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。